Grifols completes phase 3 SPARTA study
The study evaluated emphysema due to alpha-1 antitrypsin deficiency and is the largest randomized, double-blind, placebo-controlled augmentation therapy study in this population.
See the latest news and media coverage for Grifols. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global healthcare company providing plasma-derived medicines, diagnostics, and transfusion solutions
grifols.comLast updated
In short: Grifols faced regulatory scrutiny in Canada after donor deaths, restructured its global operations, and reported positive 2026 results.
The study evaluated emphysema due to alpha-1 antitrypsin deficiency and is the largest randomized, double-blind, placebo-controlled augmentation therapy study in this population.
Joanna Susan Le Couilliard replaces Iñigo Sánchez-Asiaín Mardones as independent director and Audit Committee Chair
Revenue grew from immunoglobulins, debt refinanced, organizational transformation advanced.
Adjusted EBITDA reached €854 million with margin improvement, and free cash flow pre-M&A turned positive to €91 million.
Company’s plasma collection sites have been closed to donors since Aug. 14, two days after Health Canada delivered its most ...
Grifols stock trades steadily as investors digest the latest Q2 2026 results, including modest revenue growth and improved profitability, while the plasma specialist focuses on...
Private plasma collector Grifols has revised past reports on donors who had serious injuries or died, saying now there were six such incidents at the...
The bears are cutting their positions as the company raises its earnings and reaffirms its targets for the year ...
Track Grifols and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Grifols and other trending companies.